• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

10例接受呼吸支持的肺炎患者,支气管分泌物中阿米卡星每日一次与每日两次给药的血药浓度水平比较。

Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily.

作者信息

Santré C, Georges H, Jacquier J M, Leroy O, Beuscart C, Buguin D, Beaucaire G

机构信息

Intensive Care and Infectious Diseases Unit, Lille University Medicine School, Tourcoing, France.

出版信息

Antimicrob Agents Chemother. 1995 Jan;39(1):264-7. doi: 10.1128/AAC.39.1.264.

DOI:10.1128/AAC.39.1.264
PMID:7695320
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC162523/
Abstract

In this study, concentrations of amikacin in blood and bronchial secretions of 10 patients with mechanical ventilation for acute respiratory failure due to pneumonia were measured. One-half of the patients received amikacin twice daily, and the others received once-daily administration. Concentrations in bronchial secretions of the patients treated twice daily ranged from 3 to 4 mg/liter, i.e., they were similar to those in previously published reports. Peak concentrations in bronchial secretions occurred between 3 and 4 h after the onset of infusion, and they reached 4.8 +/- 2.6 mg/liter on day 1 and 4.0 +/- 2.7 mg/liter on day 3. For the patients treated with amikacin once daily, concentrations in bronchial secretions were more than twofold higher, above 8 mg/liter for 12 h. Peak concentrations in bronchial secretions occurred between 3 and 4 h after the onset of infusion and reached 13.6 +/- 9.3 mg/liter on day 1 and 10.4 +/- 3.5 mg/liter on day 3. These concentrations are higher than the MICs for less sensitive bacterial strains, such as Acinetobacter spp. and Pseudomonas aeruginosa.

摘要

在本研究中,测定了10例因肺炎导致急性呼吸衰竭而行机械通气患者血液和支气管分泌物中的阿米卡星浓度。一半患者每日接受两次阿米卡星治疗,其余患者接受每日一次给药。每日接受两次治疗的患者支气管分泌物中的浓度范围为3至4毫克/升,即与先前发表的报告中的浓度相似。支气管分泌物中的峰值浓度在输注开始后3至4小时出现,第1天达到4.8±2.6毫克/升,第3天达到4.0±2.7毫克/升。对于每日接受一次阿米卡星治疗的患者,支气管分泌物中的浓度高出两倍多,12小时内高于8毫克/升。支气管分泌物中的峰值浓度在输注开始后3至4小时出现,第1天达到13.6±9.3毫克/升,第3天达到10.4±3.5毫克/升。这些浓度高于对较不敏感细菌菌株如不动杆菌属和铜绿假单胞菌的最低抑菌浓度。

相似文献

1
Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily.10例接受呼吸支持的肺炎患者,支气管分泌物中阿米卡星每日一次与每日两次给药的血药浓度水平比较。
Antimicrob Agents Chemother. 1995 Jan;39(1):264-7. doi: 10.1128/AAC.39.1.264.
2
Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients.每日一次使用阿米卡星治疗囊性纤维化患者铜绿假单胞菌肺部加重的耐受性、药代动力学及疗效
Eur J Pediatr. 1996 Nov;155(11):948-53. doi: 10.1007/BF02282885.
3
Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion.接受阿米卡星或妥布霉素持续输注的患者支气管分泌物中的抗假单胞菌活性。
Antimicrob Agents Chemother. 1981 Jan;19(1):72-5. doi: 10.1128/AAC.19.1.72.
4
Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia.环丙沙星在机械通气的医院获得性支气管肺炎患者支气管分泌物中的渗透情况。
Antimicrob Agents Chemother. 1994 Apr;38(4):901-4. doi: 10.1128/AAC.38.4.901.
5
The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens.阿米卡星在危重症成人和儿科患者中的药代动力学:每日一次与每日两次给药方案的比较
J Antimicrob Chemother. 1991 May;27 Suppl C:81-9. doi: 10.1093/jac/27.suppl_c.81.
6
Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections.阿米卡星每日给药一次或两次治疗全身性革兰氏阴性菌感染的比较动力学及疗效
J Antimicrob Chemother. 1991 May;27 Suppl C:73-9. doi: 10.1093/jac/27.suppl_c.73.
7
Aerosolized antibiotics in mechanically ventilated patients: delivery and response.机械通气患者雾化吸入抗生素:给药与反应
Crit Care Med. 1998 Jan;26(1):31-9. doi: 10.1097/00003246-199801000-00013.
8
Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients.囊性纤维化患者每日单次剂量阿米卡星的药代动力学和支气管扩散
J Antimicrob Chemother. 1997 Mar;39(3):431-3. doi: 10.1093/jac/39.3.431.
9
The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.两种不同剂量方案的阿米卡星在新生儿败血症中的疗效和毒性。
J Clin Pharm Ther. 2011 Feb;36(1):45-52. doi: 10.1111/j.1365-2710.2009.01152.x.
10
Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. Scandinavian Amikacin Once Daily Study Group.阿米卡星每日一次与每日两次给药方案:用于全身性革兰氏阴性菌感染的疗效与安全性。斯堪的纳维亚阿米卡星每日一次研究小组
J Antimicrob Chemother. 1993 Jun;31(6):939-48. doi: 10.1093/jac/31.6.939.

引用本文的文献

1
Pharmacokinetics of anti-Mycobacterium avium-intracellulare disease drugs in silkworms.抗鸟分枝杆菌胞内病药物在蚕体内的药代动力学。
Sci Rep. 2024 Jul 23;14(1):16931. doi: 10.1038/s41598-024-68248-3.
2
Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review-Part II.重症监护病房患者抗菌药物的组织穿透性:系统评价 - 第二部分
Antibiotics (Basel). 2022 Sep 3;11(9):1193. doi: 10.3390/antibiotics11091193.
3
Predictive Performance of Physiology-Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small-Molecule Compounds in Children.基于生理学的药代动力学剂量估计在儿科试验中的预测性能:对拜耳10种小分子化合物在儿童中的评估。
J Clin Pharmacol. 2021 Jun;61 Suppl 1(Suppl 1):S70-S82. doi: 10.1002/jcph.1869.
4
Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB).小剂量阿米卡星治疗耐多药结核病(MDR-TB)。
BMC Infect Dis. 2021 Mar 10;21(1):254. doi: 10.1186/s12879-021-05947-6.
5
Aerosol delivery during invasive mechanical ventilation: a systematic review.在有创机械通气期间输送气溶胶:系统评价。
Crit Care. 2017 Oct 21;21(1):264. doi: 10.1186/s13054-017-1844-5.
6
Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.阿米卡星、头孢西丁和克拉霉素联合治疗方案治疗肺部脓肿分枝杆菌感染失败。
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6374-6. doi: 10.1128/AAC.00990-16. Print 2016 Oct.
7
Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.结核病中空纤维系统模型中的阿米卡星最佳暴露目标
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5922-7. doi: 10.1128/AAC.00961-16. Print 2016 Oct.
8
Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model.阿米卡星在新型中空纤维脓肿分枝杆菌疾病模型中的药代动力学/药效学
Antimicrob Agents Chemother. 2015 Dec 7;60(3):1242-8. doi: 10.1128/AAC.02282-15.
9
Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.雾化抗菌药物在慢性感染性囊性纤维化患者中的药代动力学和药效学
Clin Microbiol Rev. 2014 Oct;27(4):753-82. doi: 10.1128/CMR.00022-14.
10
BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia.BAY41-6551 可实现机械通气革兰氏阴性菌肺炎患者的杀菌性气管抽吸阿米卡星浓度。
Intensive Care Med. 2012 Feb;38(2):263-71. doi: 10.1007/s00134-011-2420-0. Epub 2011 Dec 7.

本文引用的文献

1
Penetration of antibiotics into the respiratory tree.抗生素在呼吸道树中的渗透。
J Antimicrob Chemother. 1981 Sep;8(3):171-4. doi: 10.1093/jac/8.3.171.
2
Comparative studies of intermittent and continuous administration of aminoglycosides in the treatment of bronchopulmonary infections due to gram-negative bacteria.氨基糖苷类药物间歇性与持续性给药治疗革兰氏阴性菌所致支气管肺部感染的对比研究。
Rev Infect Dis. 1981 Jan-Feb;3(1):74-83. doi: 10.1093/clinids/3.1.74.
3
Penetration of antibiotics into respiratory secretions.抗生素在呼吸道分泌物中的渗透。
Rev Infect Dis. 1981 Jan-Feb;3(1):67-73. doi: 10.1093/clinids/3.1.67.
4
Does serum protein binding inhibit tissue penetration of antibiotics?血清蛋白结合会抑制抗生素的组织渗透吗?
Rev Infect Dis. 1987 Jul-Aug;9(4):713-8. doi: 10.1093/clinids/9.4.713.
5
A study of amikacin given once versus twice daily in serious infections.一项关于阿米卡星在严重感染中每日一次与每日两次给药的研究。
J Antimicrob Chemother. 1988 Jul;22(1):75-9. doi: 10.1093/jac/22.1.75.
6
Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity.通过药代动力学和杀菌活性研究确定健康志愿者中阿米卡星的最佳给药方案。
Antimicrob Agents Chemother. 1990 Apr;34(4):614-21. doi: 10.1128/AAC.34.4.614.
7
Once-daily aminoglycoside therapy.每日一次氨基糖苷类药物治疗。
Antimicrob Agents Chemother. 1991 Mar;35(3):399-405. doi: 10.1128/AAC.35.3.399.
8
Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections.阿米卡星每日给药一次或两次治疗全身性革兰氏阴性菌感染的比较动力学及疗效
J Antimicrob Chemother. 1991 May;27 Suppl C:73-9. doi: 10.1093/jac/27.suppl_c.73.
9
Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections.阿米卡星每日一次给药治疗严重感染的临床和细菌学疗效及实际情况
J Antimicrob Chemother. 1991 May;27 Suppl C:91-103. doi: 10.1093/jac/27.suppl_c.91.
10
[Pharmacokinetics of amikacin in bronchial secretions].[阿米卡星在支气管分泌物中的药代动力学]
Nouv Presse Med. 1979 Oct 31;8(42):3441-4.